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http://dxBackground: Immunologic incompatibility has implications for primary graft failure, rejection, and survival
in heart transplantation. To our knowledge, this is the first large cohort study investigating the impact of
ABO-compatible versus identical blood type matching on post heart transplantation survival.
Methods: We used a nationwide sample (2000-2010) within the United Network for Organ Sharing database.
Stratification was between ABO-identical and ABO-compatible heart transplantations for univariate and
multivariate analyses. The primary end point was graft failure from all causes. Posttransplant survival was
compared between groups using Cox proportional hazard and logistic regression models.
Results: A total of 17,951 patients met inclusion criteria, and 2684 (approximately 15%) underwent ABO-
compatible heart transplantation. ABO-compatible recipients were generally sicker than ABO-identical
recipients before transplant because more were status 1A, in the intensive care unit, and receiving mechanical
ventilatory support (P < .05). Univariate analysis correlated ABO-compatible transplants with decreased
posttransplant survival and a higher incidence of primary graft failure as cause of death (P<.05). There was
no significant difference in acute graft rejection (P ¼ .53). Multivariate analysis, however, did not demonstrate
adverse outcomes in terms of decreased graft survival (hazard ratio, 0.99; P ¼ .87). Blood type O donor grafts
were associated with poorer outcomes compared with all other types (P<.05).
Conclusions:ABO-compatible transplantation does not result in adverse outcomeswith respect to graft survival.
Blood typeO donor grafts, however, were associatedwith decreased survival. This has important implications for
current graft allocation policies, particularly for type B recipients. (J Thorac Cardiovasc Surg 2013;146:1239-46)Cardiac transplantation is an accepted therapy for treating
patients with end-stage heart failure. Although transplanta-
tion techniques and postoperative management strategies
have continued to improve in the past several decades, of
the approximately 2000 procedures performed in the United
States annually, approximately 10% of patients do not
survive the first year after transplant.1 After 1 year, annual
death rates approach 4% and approximately 50% of heart
transplant recipients are alive at 10 years.2 There are several
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Xand other complications after cardiac transplantation,
including donor cardiac function and preexisting disease,
toxicity, systemic infection, ischemic time, and mismatches
between donor and recipient heart size, sex, age, and
antigenic phenotypes.3
Because basic immunologic incompatibility is a clear
indication for posttransplant complications, it is common
practice to avoid antigenic mismatch when pairing donor
hearts with recipients. Human leukocyte antigen (HLA)
matching is applied only to highly sensitized individuals
listed for heart transplantation, although many centers are
using a strategy of ‘‘virtual’’ cross matching. Organ donors
and potential recipients are, however, paired based on ABO
blood type matching. There are 3 categories of ABOmatch-
ing: ABO identical, ABO compatible, and ABO incompat-
ible. Although adult patients typically do not receive organs
from ABO-incompatible donors, avoiding hyperacute graft
rejection, recipients sometimes receive hearts from ABO-
compatible donors. This is unlike transplant procedures
for pediatric recipients, in whom ABO-incompatible
grafts are sometimes acceptable because of a delay in the
development of natural antibodies to ABO antigens.4
Morbidity and mortality associated with recent increases
in donor shortages for all organ transplantation types have
led to a renewed interest in ABO-incompatible matching.
Although significant progress has been made on this front
in the fields of kidney and pediatric heart transplantation,
ABO compatibility is largely still a requirement for adultdiovascular Surgery c Volume 146, Number 5 1239
Abbreviations and Acronyms
ECMO ¼ extracorporeal membrane oxygenation
HLA ¼ human leukocyte antigen
ICU ¼ intensive care unit
UNOS ¼ United Network for Organ Sharing
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Xheart transplantation.4 Before ABO-incompatible adult
heart transplantation can be considered, however, it is impor-
tant to first solidify our understanding of ABO-identical and
ABO-compatible heart transplantation. In the late 1980s and
early 1990s, several anecdotal reports suggested unfavorable
outcomes among ABO-compatible (nonidentical) adult
heart transplants.5,6 Since then, however, several small,
hospital-based retrospective studies have been conducted,
which have largely determined that there are no significant
differences in outcomes of ABO-compatible versus ABO-
identical cardiac transplants.6-8 The 2012 International
Society for Heart and Lung Transplantation Heart
Transplant Report listed non–ABO-identical transplants as
a borderline significant risk factor for 5-year mortality after
transplant.9 We believe that it would be clinically useful
to compare the medium- with long-term outcomes of
ABO-compatible and ABO-identical heart transplants in a
large nationwide modern cohort study. Data gleaned from
this study could have significant implications for the
maximally efficient use of the limited donor pool.TABLE 1. ABO blood group distribution
Donor blood type
A AB B O
Total
identical*
Total
compatible*
Recipient blood type
A 6340 0 0 1302 6340 (83.0) 1302 (17.0)
AB 274 342 189 90 342 (38.2) 553 (61.8)
B 0 0 1696 829 1696 (67.2) 829 (32.8)
O 0 0 0 6889 6889 (100) 0 (0)
*Total identical and total compatible measured as proportion of each recipient blood
type.METHODS
Data Source
The United Network for Organ Sharing (UNOS) provided Standard
Transplant Analysis and Research files with deidentified donor and
recipient transplant data from October 1987 to March 2012 and recipient
follow-up data through December 2011. The database includes pros-
pectively collected demographic, donor, operative, and postoperative
information for all thoracic transplant recipients in the United States.
Study Design
We retrospectively reviewed the UNOS database from January 2000 to
December 2009. The time points were chosen to identify a modern cohort
of heart transplant patients with adequate time for follow-up. All adult
(18 years) single-organ heart transplants were included. Transplants
were primarily stratified by transplant donor-recipient ABO blood type
matching (identical vs compatible). Transplants without available data
on donor and/or recipient ABO types were excluded from the study (n¼ 1).
Outcome Measures
Demographic and clinical characteristics of all heart transplant donors and
recipients were examined. The primary end point was all-cause graft failure
during the study period. Secondary outcomes of interest included 30-day
mortality, length of hospital stay, graft rejection, and recipient cause of death.
Statistical Analysis
Baseline demographic and clinical characteristics between the primary
study cohorts were compared using the Student t test for continuous
variables and the c2 test for categorical variables. For all Student t tests1240 The Journal of Thoracic and Cardiovascular Surconducted, normality was assessed using skewness and kurtosis. Survival
was modeled using the Kaplan-Meier method, with statistical differences
between survival curves assessed using the log-rank (Mantel-Cox) test.
Univariate and unadjusted 30-day and 1-, 3-, 5-, and 10-year graft survival
analyses were also conducted using the c2 test. Multivariate analysis was
conducted using both the Cox proportional hazards regression model and
a logistic regression model. To adjust for potential confounders and
accurately determine factors associated with decreased graft survival,
variables describing baseline demographic and clinical characteristics
that were significantly different (P<.05) between the 2 study cohorts on
univariate analysis were included in the multivariate models. For the
logistic regression analysis, variables were removed from the model in a
stepwise manner until all included variables (except ABO compatibility
and the variable of interest) were statistically significant (P<.05).
Statistical significance was established at P< .05 (2 tailed), and all
hazard ratios are presented with 95% confidence intervals. All statistical
analysis was generated using SAS software, version 9.3, of the SAS System
for Windows (SAS Institute Inc, Cary, NC).RESULTS
The UNOS database contained records of 15,267
ABO-identical transplants and 2684 ABO-compatible
transplants during the study period from January 2000 to
December 2009 that fit the study’s inclusion criteria
(Table 1). Of the transplant recipients with blood types A,
B, and AB, the frequency of ABO-compatible transplants
was 17.0%, 32.8%, and 61.8%, respectively. Blood type
O recipients can only receive ABO-identical grafts.
The baseline demographic characteristics of both donors
and recipients from these transplant surgical procedures are
summarized in Tables 2 and 3, respectively. The allograft
donors from both cohorts were well matched based on
sex, age, mean left ventricular ejection fraction, cause of
death, and a history of hypertension, diabetes, and cigarette
use. Therewas a significant difference (P<.05) between the
2 groups in terms of donor ethnicity and history of cancer.
The baseline demographic and clinical characteristics of
heart recipients in the ABO-identical and ABO-compatible
cohorts differed (P<.05) with respect to sex, age, ethnicity,
wait list status at transplant, status before transplant
(in intensive care unit [ICU], in hospital, or not hospital-
ized), life support before transplant, and mean graft
ischemic time and total bilirubin. More ABO-compatible
transplant recipients were wait list status 1A (50.3%) than
ABO-identical transplant recipients (28.3%, P < .001).gery c November 2013
TABLE 2. Donor characteristics stratified by ABO blood type
matching
Variable
ABO identical
(n ¼ 15,267)*
ABO
compatible
(n ¼ 2684)*
P
valuey
Female sex 4306 (28.2) 787 (29.3) .24
Mean (SD) donor age, y 31.54  12.35 31.40  12.53 .58
Ethnicity
White 10,687 (70.0) 1697 (63.3) <.001
Black 1938 (12.7) 387 (14.4) .01
Hispanic or Latino 2259 (14.8) 518 (19.3) <.001
Asian 213 (1.4) 46 (1.7) .20
History of hypertension 1829 (12.0) 336 (12.6) .42
History of cancer 254 (1.7) 64 (2.4) .01
History of diabetes 343 (2.3) 68 (2.5) .35
History of cigarette use 3903 (25.8) 698 (26.2) .67
Cause of death
Anoxia 1562 (10.2) 288 (10.7) .44
Cerebrovascular/stroke 3839 (25.2) 713 (26.6) .12
Head trauma 9427 (61.8) 1615 (60.2) .12
CNS tumor 158 (1.0) 25 (0.93) .62
Mean (SD) LVEF 61.57  7.83 61.62  8.02 .74
CNS, Central nervous system; LVEF, left ventricular ejection fraction; SD, standard
deviation. *Some patients were excluded from each analysis because of missing
data fields or erroneously imputed data in the database. yP value based on Student
t test for continuous variables and the c2 test for categorical variables (P< .05 is
considered statistically significant).
TABLE 3. Recipient characteristics stratified by ABO blood type
matching
Variable
ABO identical
(N ¼ 15,267)*
ABO compatible
(N ¼ 2684)*
P
valuey
Female sex 3584 (23.5) 708 (26.4) .001
Mean (SD) recipient age, y 51.91  12.26 51.12  12.87 <.001
Ethnicity
White 11,286 (73.9) 1882 (70.1) <.001
Black 2399 (15.7) 498 (18.6) <.001
Hispanic or Latino 1110 (7.3) 179 (6.7) .27
Asian 311 (2.0) 102 (3.8) <.001
Wait list status at transplant
1A 5771 (37.8) 1350 (50.3) <.001
1B 6040 (39.6) 928 (34.6) <.001
2 3450 (22.6) 405 (15.1) <.001
Status before transplant
In ICU 4321 (28.3) 1083 (40.4) <.001
In hospital (not ICU) 2853 (18.7) 545 (20.3) .05
Not in hospital 8093 (53.0) 1056 (39.3) <.001
Life support at transplant
ECMO 67 (0.44) 25 (0.93) .001
IABP 737 (4.8) 234 (8.7) <.001
IV inotropes 6,786 (44.5) 1,330 (49.6) <.001
Inhaled NO 36 (0.24) 7 (0.26) .81
Ventilatory support 387 (2.5) 122 (4.5) <.001
VAD 3609 (23.6) 608 (22.7) .27
History of dialysis 368 (2.4) 76 (2.8) .2
History of cardiac surgery 2918 (19.1) 543 (20.2) .18
History of malignancy 739 (4.8) 137 (5.1) .56
History of diabetes 3460 (22.7) 600 (22.4) .73
History of cigarette use 3848 (25.2) 700 (26.1) .34
Mean (SD) ischemic time, h 3.23  1.05 3.11  1.00 <.001
Mean (SD) serum creatinine
at Tx, mg/dL
1.31  0.56 1.33  0.63 .14
Mean (SD) total bilirubin,
mg/dL
1.23  1.94 1.37  2.01 <.001
CMV IgG positive 8675 (62.6) 1567 (63.7) .32
CMV IgM positive 816 (8.8) 164 (9.6) .24
ICU, Intensive care unit; ECMO, extracorporeal membrane oxygenation; IABP, intra-
aortic balloon pump; IV, intravenous; NO, nitric oxide; VAD, ventricular assist device;
Tx, treatment; CMV, cytomegalovirus; SD, standard deviation; IgG, immunoglobulin
G; IgM, immunoglobulin M. *Some patients were excluded from each analysis
because of missing data fields or erroneously imputed data in the database. yP value
based on Student t test for continuous variables and the c2 test for categorical variables
(P<.05 is considered statistically significant).
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the ICU before transplant compared with only 28.3% of
ABO-identical recipients (P<.05). When compared with
ABO-identical transplant recipients, ABO-compatible
transplant recipients were more frequently on life support
before transplant (P < .05), including extracorporeal
membrane oxygenation (ECMO), intra-aortic balloon
pump, intravenous inotropes, and ventilator support.
There was no statistical difference between the 2 groups
in terms of ventricular assist device use (P ¼ .266). Graft
ischemic time and total bilirubin also differed between the
2 study cohorts (P < .001); ABO-identical transplant
recipients had a longer mean ischemic time and lower
total bilirubin (3.23 hours, 1.25 mg/dL) compared with
ABO-compatible transplant recipients (3.11 hours, 1.48
mg/dL).
Table 4 showsunadjusted 30-day and1-, 3-, 5-, and10-year
graft survival for ABO-identical and ABO-compatible heart
transplant recipients. Recipients of ABO-identical grafts
had increased graft survival (P<.05) compared with ABO-
compatible recipients at 30 days (94.4% vs 93.3%), 1 year
(87.0% vs 84.4%), 3 years (76.3% vs 73.4%), and 5 years
(63.1% vs 60.0%) after transplant. Therewas no statistically
significant difference in graft survival at 10 years after
transplant (P ¼ .21). In addition, there was no difference in
the incidence of rejection between transplant and discharge
(P ¼ .53) and mean length of stay as well as length of stay
between transplant and discharge (P ¼ .97).The Journal of Thoracic and CarTransplant recipient cause of death was similar between
ABO-identical and ABO-compatible recipients, except for
mortality due to primary graft failure and malignancy
(Table 5). More ABO-compatible heart recipients died
from primary graft failure than ABO-identical recipients
(8.7% vs 5.8%; P ¼ .003). Interestingly, ABO-identical
transplant recipients showed a greater incidence of death
due to malignancy than the ABO-compatible cohort
(9.8% vs 6.6%; P ¼ .007).
When graft survival was compared between the 2 study
cohorts using the Kaplan-Meier method (Figure 1), ABO-
identical recipients showed a slightly higher degree of graftdiovascular Surgery c Volume 146, Number 5 1241
TABLE 4. Outcomes stratified by ABO blood type matching
Variable
ABO identical
(N ¼ 15,267)
ABO compatible
(N ¼ 2684)
P
value*
30-d Survival 14,396 (94.4) 2500 (93.3) .02
1-y Survival 13,241 (87.0) 2258 (84.4) <.001
3-y Survival 10,199 (76.3) 1720 (73.4) .003
5-y Survival 6960 (63.1) 1140 (59.9) .009
10-y Survival 1147 (17.8) 187 (16.3) .21
Rejection between transplant
and discharge
1319 (8.6) 222 (8.3) .53
Mean (SD) length of stay,
transplant to discharge, d
20.04  25.86 20.05  22.14 .97
Survival data based on graft survival time, after transplant; SD, standard deviation.
*P value based on Student t test for continuous variables and the c2 test for categorical
variables (P<.05 is considered statistically significant).
FIGURE 1. Kaplan-Meier graft survival analysis, ABO-compatible (C)
versus ABO-identical (I) transplants. Solid line, ABO-compatible trans-
plants; dashed line, ABO-identical transplants. A table is given with the
number of patients at risk at each time point. The P value corresponds to
Mantel-Cox log-rank test results.
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ence was not statistically significant (P ¼ .09).
The multivariate Cox proportional hazards regression
model (Table 6) demonstrated 6 variables of significance
(P<.05) for the outcome measure of graft failure: recipient
ethnicity, ventilatory support at transplant, pretransplant
ECMO use, graft ischemic time, total bilirubin, and patient
status before transplant (in ICU, in hospital, or not hospital-
ized). Although univariate analysis showed ABO blood type
matching (identical vs compatible) to have a significant
impact on the incidence of graft failure, this effect was
eliminated when controlling for potential confounders in
the multivariate model (hazard ratio [ABO compatible],
0.991; P ¼ .865).
In the multivariate logistic regression model showing risk
factors for 30-day graft failure posttransplant, variables of
significance (P < .05) were life support at transplant,
including intravenous inotropes, ventilator support, and
pretransplant ECMO use; ischemic time; wait list status at
transplant; status before transplant (in ICU, in hospital, or
not hospitalized); and total bilirubin (Table 7). Once again,TABLE 5. Recipient cause of death stratified by ABO blood type
matching
Variable
ABO identical
(N ¼ 4000)
ABO compatible
(N ¼ 724) P value*
Graft failure: all causes 709 (17.7) 149 (20.6) .07
Primary failure 231 (5.8) 63 (8.7) .003
Acute rejection 252 (6.3) 41 (5.7) .51
Chronic rejection 108 (2.7) 25 (3.5) .26
Infection 615 (15.4) 119 (16.4) .47
Cardiovascular 773 (19.3) 144 (19.9) .72
Pulmonary 259 (6.5) 45 (6.2) .79
Cerebrovascular 180 (4.5) 23 (3.2) .11
Hemorrhage 98 (2.5) 17 (2.4) .87
Malignancy 392 (9.8) 48 (6.6) .007
Renal failure 102 (2.6) 23 (3.2) .33
Multiple-organ failure 417 (10.4) 78 (10.8) .78
*P value based on the c2 test for categorical variables (P<.05 is considered statisti-
cally significant).
1242 The Journal of Thoracic and Cardiovascular Surwhen controlling for potential confounding variables, ABO
matching (identical vs compatible) was not statistically sig-
nificant (P ¼ .08).
Posttransplant graft survival was also compared among
different donor ABO blood groups using the Kaplan-
Meier method (Figure 2). This analysis demonstrated
decreased graft survival associated with type O donors
and increased survival associated with type A donors
(P<.05) when compared with all other blood types. Type
B and AB donors were not associated with either increased
or decreased graft survival when compared with the other
ABO blood types (P>.05). When looking at posttransplant
graft survival in blood type B recipients (Figure 3), blood
type O donor hearts were associated with decreased graft
survival when compared with type B grafts (P<.05).DISCUSSION
Since the advent of cardiac transplantation in the 1960s,
physicians havemade considerable efforts to improve short-
and long-term transplant outcomes by investigating the
causes of graft rejection and generalized graft failure.
Immunologically, as with other transplanted organs, this
has involved minimizing antigenic mismatches between
graft donors and recipients. Because of the high demand
and comparatively low supply of available organs for trans-
plant, emphasis has also been placed on generating graft
allocation policies that are fair and effective. Because of
the multifactorial nature of graft failure, these efforts have
led to a debate about the impact of ABO blood type compat-
ibility and the importance of HLA matching on adult heart
transplant outcomes.
For HLA matching, Opelz and Wujciak10 definitively
showed a strong relationship between donor-recipientgery c November 2013
TABLE 7. Multivariable logistic regression model: 30-day graft
failure
Variable
Odds ratio
(95% confidence limits) P value*
ABO compatible 1.23 (0.97-1.56) .08
Life support at transplanty
All 1.89 (1.40-2.54) <.001
IV inotropes 0.58 (0.46-0.74) <.001
Ventilatory support 2.78 (1.87-4.14) <.001
ECMO 7.53 (4.18-13.55) <.001
Ischemic time 1.24 (1.15-1.34) <.001
Wait list status at transplantz
1B 1.23 (0.97-1.56) .09
2 1.68 (1.19-2.36) .003
Status before transplantx
In ICU 1.60 (1.23-2.07) <.001
In hospital (not ICU) 1.16 (0.86-1.56) .34
Total bilirubin 1.08 (1.05-1.10) <.001
IV, Intravenous; ECMO, extracorporeal membrane oxygenation; ICU, intensive care
unit. *P value based on logistic regression model (P<.05 is considered statistically
significant). yVs no life support. zVs UNOS wait list status 1A. xVs not in hospital.
FIGURE 2. Kaplan-Meier graft survival analysis, donor type O versus all
other heart transplants. Solid line, donor ABO type O; dashed line, all other
donor types. A table is given with the number of patients at risk at each time
point. The P value corresponds to Mantel-Cox log-rank test results.
TABLE 6. Multivariate Cox proportional hazards regression model
Variable
Hazard ratio (95%
confidence limits) P value*
ABO compatibley 0.99 (0.89-1.10) .87
Sex (male vs female) 0.95 (0.88-1.03) .24
Donor ethnicityz
Black 1.08 (0.98-1.20) .14
Hispanic 1.00 (0.90-1.10) .95
Asian 1.13 (0.87-1.47) .37
Recipient ethnicityz
Black 1.42 (1.30-1.56) <.001
Hispanic 1.09 (0.94-1.25) .25
Asian 0.92 (0.70-1.19) .52
Life support at transplantx
All 1.07 (0.94-1.21) .32
IABP 0.98 (0.81-1.20) .85
IV inotropes 0.95 (0.85-1.06) .34
Ventilatory support 1.88 (1.50-2.37) <.001
ECMO 2.60 (1.72-3.83) <.001
Ischemic time 1.09 (1.06-1.13) <.001
Wait list status at transplantk
1B 1.00 (0.90-1.11) .95
2 1.08 (0.94-1.23) .29
Status before transplant{
In ICU 1.24 (1.10-1.39) <.001
In hospital (not ICU) 1.13 (0.99-1.28) .07
Total bilirubin 1.03 (1.02-1.04) <.001
IABP, Intra-aortic balloon pump; IV, intravenous; ECMO, extracorporeal membrane
oxygenation; ICU, intensive care unit. *P value based on multivariate Cox propor-
tional hazards regression model, using factors significant on univariate analysis
(P<.05 is considered statistically significant). yVs ABO incompatible. zVs white
ethnicity. xVs no life support. kVs UNOS wait list status 1A. {Vs not in hospital.
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plant graft survival through the collaborative transplant
study. More recent studies have demonstrated that the pres-
ence of circulating HLA-directed donor-specific alloanti-
bodies are correlated with increased morbidity and
mortality, cardiac allograft vasculopathy, and increased
rates of graft rejection.11,12
Regarding ABO blood type matching, initial reports sug-
gested that ABO-compatible transplants are less efficacious
than ABO-identical ones.5,6 More recently, investigators
have disagreed with this conclusion.7,8,13 A common
problem of past studies has been a relatively small sample
size precluding strong statistical power. In our analysis,
we demonstrated that ABO-identical and ABO-compatible
heart transplants have similar outcomes in terms of graft sur-
vival. By analyzing all adult cardiac transplants performed
between 2000 and 2010, we were able to use a modern
cohort of patients with a significantly larger sample size.
Although our univariate analysis did show statistically
significant differences in survival at 30 days and 1, 3, and
5 years posttransplant between the 2 study cohorts, these dif-
ferences did not hold up after controlling for potential con-
founding variables in the multivariable models.The Journal of Thoracic and CarOne of these possible confounding variables was Organ
Procurement and Transplantation Network wait list status
at transplant. Interestingly, according to our analysis,
ABO-compatible heart recipients were more often status
1A at transplant when compared with ABO-identical recip-
ients (50.3% vs 37.8%). In addition, ABO-compatible re-
cipients were more likely to be in the ICU and receiving
several different mechanisms of life support, including
ECMO, intra-aortic balloon pump, parenteral inotropes,
and ventilator support, than ABO-identical heart recipients.
These data suggest that ABO-compatible recipients are
generally sicker than ABO-identical recipients, contrib-
uting to a worse prognosis. This is further supported bydiovascular Surgery c Volume 146, Number 5 1243
FIGURE 3. Kaplan-Meier graft survival analysis, donor type B versus
donor type O heart transplants. Solid line, donor ABO type B; dashed
line, donor ABO type O. A table is given with the number of patients at
risk at each time point. The P value corresponds to Mantel-Cox log-rank
test results.
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transplant mean total bilirubin compared with ABO-
identical recipients (1.48 vs 1.25 mg/dL), indicating a
greater degree of heart failure.
On analysis of recipient cause of death by ABO blood
type matching, ABO-compatible recipients died as a result
of primary graft failure more frequently than recipients of
ABO-identical hearts (8.7% vs 5.8%). Heart transplant
recipient mortality due to primary graft failure is frequently
associated with ‘‘marginal’’ donors or recipients.14 This
seems to suggest that ABO-compatible transplants involve
more marginal recipients and/or donors than ABO-
identical transplants.
In multivariate analysis, ABO blood typematching (iden-
tical vs compatible) was not a statistically significant pre-
dictor of decreased cumulative or 30-day graft survival.
Instead, the Cox proportional hazards model indicated
recipient ethnicity (specifically, African American), life
support at transplant (ventilator support and ECMO), graft
ischemic time, total bilirubin, and recipient status before
transplant to be significant predictors of decreased graft sur-
vival after transplant. The multivariate logistic regression
model indicated many of these variables (ie, life support
at transplant, ischemic time, bilirubin, and status before
transplant) and wait list status as statistically significant pre-
dictors of graft failure within 30 days of transplant. Other
studies have demonstrated similar results regarding risk fac-
tors for decreased survival and increased graft failure after
heart transplants.15-17
The observed discrepancies in the effect of ABO compat-
ibility on cardiac transplant outcomes between our univariate
and multivariate models can be explained by investigating
the impact of individual donor ABO blood types on graft sur-
vival. We discovered, in both our univariate and multivariate1244 The Journal of Thoracic and Cardiovascular Suranalyses, that donor ABO blood type O is associated with
decreased graft survival when compared with all other types.
Because blood type O donor grafts are transplanted into re-
cipients of all blood types (Table 1), the poorer outcomes
associated with type O donor hearts could be skewing the re-
sults of our univariate analysis to misleadingly suggest that
ABO-compatible transplants result in worse outcomes than
ABO-identical ones. We confirmed this hypothesis by
removing all type O donors from our univariate analysis,
which demonstrated no statistically significant difference
in graft survival at all time points after transplant between
ABO-identical and ABO-compatible cohorts (P>.05).
The poor outcomes associated with type O donor grafts
do have implications for organ allocation policies. Accord-
ing to the Organ Procurement and Transplantation Network
policy 3.7.8.1 from February 2013, ‘‘Blood type O donors
shall only be allocated to blood type O or blood type B pa-
tients’’ before being offered to blood type A or AB patients.
Given the poor outcomes associated with blood type
O grafts in type B recipients, this policy may need to be
reviewed. Interestingly, previous studies have shown that
blood type O individuals experience decreased rates of
morbidity regarding conditions such as congestive heart
failure.18 Further research should be conducted to investi-
gate possible explanations for the poor outcomes associated
with blood type O donor hearts and the best organ allocation
scheme for managing these grafts.
Limitations
Such as any other retrospective cohort study, this investi-
gation was limited by the strength of the primary database in
terms of completeness, accuracy, quality, and appropriate-
ness of the predictor variables. Although the data set pro-
vided by UNOS was extremely comprehensive and
included many important variables that described baseline
donor and recipient information and postoperative out-
comes, the study could have been strengthened if additional
data were available to us. Furthermore, because it is a large
national database compiled over many years, the accuracy
of all the patient information coded in the UNOS database
cannot be guaranteed. We are confident, however, that given
the nature of our investigation, an analysis of a large na-
tional cohort of patients, any errors in patient data will
not bias our results.
CONCLUSIONS
In the past decade, ABO-compatible donor hearts were
preferentially given to sicker transplant recipients. As
demonstrated in this study, transplantation using ABO-
compatible adult hearts does not result in adverse outcomes
with respect to graft survival and incidence of acute rejec-
tion compared with ABO-identical grafts. Therefore,
ABO-compatible and ABO-identical heart transplant
matches should be viewed equally in clinical decisiongery c November 2013
Jawitz et al Cardiothoracic Transplantationmaking and to maximize efficiency within the available
donor pool. This will help optimize the use of donor organs,
an extremely important, yet scarce, resource. In doing so,
waiting times could be shortened and overall outcomes
could be improved. In addition, because ABO blood type
O donor grafts are associated with decreased survival after
transplant, current organ allocation policies should be re-
viewed, particularly those pertaining to ABO blood type
B heart transplant recipients.
We thank Ms. Elsa Su, MS (Statistics), for helping in the prep-
aration of the manuscript and the Yale School of Medicine Office
of Student Research for support.T
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Dr Nader Moazami (Cleveland, Ohio). Well, let me start by
congratulating you on your presentation. Many of us who were
at your stage in our careers have not had the opportunity to present
in such a prestigious forum, and I am hopeful that this bodes well
for your future in academic surgery. I will start with a few general
comments and then at the end ask my questions.
I think the topic and title of this talk are interesting. For many
transplant clinicians, the issue of ABO-compatible transplantation
seems to have been put to rest, particularly in the era of continued
organ shortage. In fact, the current trend in the literature is largely
focused on a completely opposite and different strategy, that is,
ABO-incompatible transplantation. This strategy has been widely
applied in the renal world and has led to an increase in the number
of living-related kidney transplantations. A similar strategy has
been successfully applied in the neonatal and pediatric heart trans-
plant population for whom the availability of organs in a timely
fashion is limited.
Now, most of us think of ABO as antigens expressed on the sur-
face of red blood cells, but in fact they are widely expressed on
endothelial cells, including those of the heart. The specter of anti-
body-mediated hyperacute rejection is what has made ABO-
incompatible heart transplantation a hurdle in adults and, in the
current era of LVADs, of much less interest. So the question is,
where does ABO-compatible heart transplantation fit in our overall
practice and how important is this in terms of graft and patient sur-
vival, a question that you have attempted to analyze in your presen-
tation today.
I am going to draw 3 broad conclusions from your presentation
and follow thosewith questions, and I will wait for your answer for
each one.
As you know, graft failure is multifactorial and depends
on many donor and recipient variables, some of which you have
accounted for in your analysis, particularly those markers that
identify sicker patients. I am not sure if in your analysis other
well-known variables, such as pulmonary hypertension, recipient
and donor age, and ischemic times, have been accounted for.
Did you look at any of these factors for graft failure in your multi-
variable model?
Mr Jawitz. First of all, thank you, Dr Moazami, for your enthu-
siastic support and criticism. As a medical student planning to pur-
sue a career in surgery, it really means a lot to me.
To answer your question, we were able to look at some of those
variables in the database. Unfortunately, we were limited by the
variables that were coded in the UNOS database, and in some in-
stances there was a significant amount of data missing. In our
multivariate analysis, however, we actually did show that total bili-
rubin time, ethnicity, and a number of other variables were actually
independently associated with poorer outcomes. Pulmonary hy-
pertension was included in our cause of death analysis, but not
in our pretransplant univariate analysis of recipient baseline
characteristics.diovascular Surgery c Volume 146, Number 5 1245
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XDrMoazami. That brings me to the second conclusion that you
drew, and that is that ABO-compatible heart transplantation is
an acceptable strategy and unlikely to impact short- or long-term
survival. In fact, the International Society of Heart and Lung
Transplantation, which is a large registry of all transplant recipi-
ents, on an annual basis evaluates all transplant-related data. Inter-
estingly, occasionally a small improved survival difference has
been seen between ABO-identical and ABO-compatible donors.
However, this generally has been negligible and largely accounted
for by many other markers of immunogenicity, namely, the degree
of HLA mismatching. This brings me to the next question for you.
In looking at short- and long-term results, the immunogenicity
of MHC antigens and also presence of donor-specific antibodies
play a large role in graft viability. In your analysis, were any of
these factors, specifically HLA matching, panel-reactive antibody
levels, or cross match results, available and accounted for?
Mr Jawitz. Thank you very much. That is an excellent ques-
tion. Yes, it is true that HLA matching is extremely important in
long-term graft outcomes. I believe, in the last 10 years, research
conducted by Opelz and colleagues, the collaborative transplant
study, showed that 2 HLA-A, HLA-B, or HLA-DR mismatches
were actually associated with 25% increased graft failure
compared to 0 or 1 mismatch within 3 years of transplant. In terms
of our study, we really wanted to keep it simple and specifically
focus on ABO blood types, namely, ABO-compatible versus
ABO-identical matches. In addition, a recently published article
specifically looking at renal transplantation showed no correlation
between HLA matching and ABO blood type matching.
I do agree that HLA typewould be interesting to look at and see,
specifically, how differences in HLA blood type between donors
and recipients have impacted these data.
Dr Moazami. Finally, I caution against one of your conclu-
sions, which is regarding decreased survival of blood type O do-
nors for, specifically, blood type B recipients. The UNOS
organization mandate is based on 2 major premises: (1) the equity
in organ allocation and (2) in maximizing the survival benefit for
recipients that are at the highest risk of dying. The policy of allo-
cating O donor hearts to type O recipients first and then type B is a
reflection of this policy. Type O recipients can only receive organs
from type O and, hence, typically have longer wait times on the
list. Similarly, type B in the United States comprises only about
10% of the population and, hence, they are at a disadvantage
compared to type A blood that comprises about 40% of the
population.
So, with the Kaplan-Meier curve that you showed at the end in
terms of the blood donor O to B recipients, were any of these risk
adjusted, and is it possible that if we correct for some of the factors
that I mentioned previously related to immunogenicity that these
small differences in survival will disappear?
Mr Jawitz. Yes, that is a good question. We actually looked at
primary graft failure as an outcome between donor type O hearts1246 The Journal of Thoracic and Cardiovascular Surgoing to type B individuals and type B hearts going to type B re-
cipients, and we actually found out that compatible matches, that
is, type O hearts going to type B recipients, were actually associ-
ated with increased rates of primary graft failure.
As for the current OPTN policy and organ allocation scheme,
you are right, the reason that blood type B recipients preferentially
receive type O organs is because of the short supply of type B
hearts in this country.When approaching a potential change in pol-
icy, it would be important to ensure that that any decrease in donor
heart availability for type B recipients would be more than made
up for by significantly improved posttransplant outcomes. More
analysis is certainly needed before we would feel comfortable rec-
ommending such a policy.
Dr Moazami. Thank you.
Dr DavidMcGiffin (Birmingham, Ala). I just want to follow on
from that point. Youmentioned in your manuscript and in your talk
about the poorer survival of blood O to B. You have demonstrated
that there are no immunological consequences of that, but O to B is
most likely a surrogate for sicker donors and sicker recipients. On
that basis, though, howwould you change the allocation system for
what is probably an immutable problem?
Mr Jawitz. That is a good question. As Dr Moazami pointed
out, the reason why blood type B recipients are receiving blood
type O donor hearts is because of the comparative shortage of
type B donor hearts in this country. To really change the current
allocation scheme, we would have to take into account the poten-
tial of actually harming type B individuals by changing the policy.
I do not think there is a really great answer to how to specifically
change the policy at this point and I certainly believe that more
research is warranted.
The senior author on this paper actually believes that changing
the pretransplant management of type B patients, that is instead of
rushing to transplant themwith a type O donor heart, perhaps using
an LVAD as a bridge to transplant as you wait for an identical type
B donor graft, may be a method of mitigating this problem.
Dr Pieter Kappetein (Rotterdam, The Netherlands). You
showed that there is a significant difference between the different
groups, especially for the blood type O patients. Of course, this is a
large group of patients. For example, in the A-B group, you have
few patients, and might that not be a type II error that maybe there
might also be a difference there because you do not have enough
patients that you do not see the difference?
Mr Jawitz.You are absolutely right. Wewere limited by the data-
base that we had and in several instances due to incomplete data and a
lack of certain variables, we were unable to answer all of our
questions.
Dr Kappetein. And, of course, therefore, in a group where you
have enough patients you can identify easier a difference and while
in the groups that are smaller there might be a difference as well
but it might be more difficult to identify.
Mr Jawitz. Yes, you are correct.gery c November 2013
